Australia's most trusted
source of pharma news
Posted 20 January 2026 AM
Four new drugs are on their way to Australia, with another expanding its indicated population and a sixth becoming a new use for an old drug.
Newly-minted Pharming Australia is seeking a second indication for its first drug, Joenja. The drug received a PBAC recommendation in July for the treatment of symptomatic activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents aged 12 years and older, for which it had previously received priority review and orphan drug designation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.